Majority of these events were dominated by women including headache in GLP1-RA users [risk ratio (95% confidence interval), 7.97 (1.01–62.78)], genital infection and urinary tract infections (all reported by women), in SGLT2i users, edema (fluid retention) [12.56 (2.91–54.13)] in TZD users, hyperglycemia [15.35 (8.54–27.60)] in insulin users, and urinary tract infection [5.66 (2.14–14.95)] in DPP-4 inhibitor users. This evidence concerns the gene INS and Headache.